This trial is evaluating whether Oral Vancomycin will improve 1 primary outcome and 1 secondary outcome in patients with Relapse. Measurement will happen over the course of Day 0 - data will be collection upon enrollment.
This trial requires 130 total participants across 2 different treatment groups
This trial involves 2 different treatments. Oral Vancomycin is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"The National Health Survey (NHES) estimates that around one fifth of all individuals with a history of cannabis use experience recurrent use, with as few as 3.8% of those experiencing more severe consequences. Data from a recent study suggest that the lifetime use may be considerably higher than reported from surveys. As such, the numbers may underestimate relapse rates, and highlight the need for improved surveillance and improved communication of relapse rates among service providers and their patients." - Anonymous Online Contributor
"The symptoms of relapse in bipolar disorder have been discussed with a range of phenomenological descriptions. The evidence in the present study is consistent with the thesis that the manifestation of symptoms in bipolar disorder requires the coexistence of a psychotic episode during the depressive and manic phases. The authors also discuss the possibility that the experience of rebound manic symptoms, which feature prominently in some accounts, may have been influenced by the presence of cognitive biases. This article has been reproduced anonymously in accordance with its publication guidelines." - Anonymous Online Contributor
"There are different ways that remission can be defined. There are no hard and fast rules and the individualized definition of the end point of treatment is important. In conclusion, to define a cure requires many variables of study, all of which must be taken into account to make a logical decision on treatment. A definitive "cure" does not exist and treatments are never fully perfect." - Anonymous Online Contributor
"The risk of relapse in patients with lung cancer is dependent on two factors, the initial tumor size and grade, and type of tumor (pTNM stage). Patients with surgically resected N2 NSCLC have a higher risk for relapse compared to patients with stage I NSCLC." - Anonymous Online Contributor
"Relapse is common in those who experience relapse after remission from their original depressive episode. Antidepressants may reduce this risk by about 36% in those with the most severe depressive disorder (MDD)." - Anonymous Online Contributor
"Despite initial success, relapse is a common occurrence. Relapse after ablation occurs in up to half of cases. Patients who are relapsing are usually receiving a new biologic agent. A more detailed definition of ablation of recurrence is required in this subgroup of patients to permit appropriate treatment." - Anonymous Online Contributor
"The primary cause of relapses is unknown (as yet); however, some factors are hypothesized to play a role: 1) loss of treatment benefit 2) loss of treatment efficacy 3) loss of target engagement. If patients have more than one relapse, different causes should be considered for each relapse." - Anonymous Online Contributor
"The usual definition of CVC is difficult to apply to these patients, given that they generally do not have any obvious sign of endocarditis on the initial clinical assessment. This issue may be overcome by defining oral vancomycin therapy as the first step in the treatment of endocarditis and then evaluating the requirement for its continuation or discontinuation on the basis of the presence or absence of clinical evidence of relapse." - Anonymous Online Contributor
"Oral vancomycin is efficacious at the usual dosages for the treatment of bloodstream infections in pediatric patients, and is generally well tolerated. It may be used safely to treat localized infections." - Anonymous Online Contributor
"In our study, the majority of subjects that were given oral vancomycin were also given at least one other treatments. Oral vancomycin has a clear therapeutic benefit and a better safety-effect profile when used as a monotherapy compared to when used in combination with other antibiotics." - Anonymous Online Contributor
"Currently, many patients experience remission of the cancer before the diagnosis of CLL. One of the main goals is to reduce the number of patients who experience a relapse and hopefully cure CLL. It is also a common sense that doctors aim to avoid treatment and medications that trigger severe side effects when the diagnosis of CLL is already made as early as possible." - Anonymous Online Contributor
"Oral vancomycin is generally well tolerated and generally well tolerated by patients. In clinical practice, these side effects usually go into remission when vancomycin is stopped and patients are monitored regularly after this. There are no clear recommendations about when this should happen but it may be prudent to review and make changes to the vancomycin protocol if patients are unhappy or have problems with adherence or have experienced the side effects above." - Anonymous Online Contributor